<scp>SS</scp>18‐<scp>SSX</scp>‐regulated miR‐17 promotes tumor growth of synovial sarcoma by inhibiting p21<scp>WAF</scp>1/<scp>CIP</scp>1Yusuke Minami, Shinya Tanaka|Cancer Science|2014Cited by 34
Surgical Treatment of Intramuscular MyxomaSermsak Sukpanichyingyong, Joji Miyawaki, Seiichi Matsumoto et al.|Indian Journal of Orthopaedics|2021Cited by 17
Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue SarcomaYasuyoshi Sato, Shunji Takahashi, Kenji Nakano et al.|Cancers|2021Cited by 12
Definitive surgery of primary lesion should be prioritized over preoperative chemotherapy to treat high-grade osteosarcoma in patients aged 41–65 yearsKeiko Hayakawa, Atsushi Okawa, Seiichi Matsumoto et al.|Journal of Orthopaedics and Traumatology|2020Cited by 11
The Role of Neoadjuvant Chemotherapy in Resectable Primary Synovial SarcomaYusuke Minami, Yusuke Tsuda, Taisuke Tanizawa et al.|Anticancer Research|2020Cited by 10